
Opinion|Videos|March 31, 2025
Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease
Experts discuss the relationship between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD) risk, with findings from a large US population study, and explore how these findings could impact clinical practice and the management of patients at risk for ASCVD.
Advertisement
Video content above is prompted by the following:
- In the introduction, I mentioned that Lp(a) is considered an independent and significant risk factor for ASCVD and aortic stenosis. Dr Wong, you recently studied the relationship between Lp(a) level and ASCVD risk in a large US population. Could you describe your findings?
- Dr Saseen, how might findings like these impact clinical practice?
Advertisement
Related to this article

Kidney Week 2026 brought strong IgAN data, looked back on 5 years of value-based kidney care, and highlighted evidence of persistent CKD care gaps.

Elagolix 150 mg was noninferior to dienogest 2 mg for reducing moderate-to-severe endometriosis pain in a phase 3 trial of 230 women in India.

Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.

Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.

An analysis of AccessHope case reviews found that experts recommended changes in more than 80% of cases. About half were implemented, saving a median of $18,636 per case.

Nearly half of patients with chronic HBV or HCV also had MASLD, tied to worse fatigue and quality of life.

From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.
Advertisement
Advertisement
Trending on AJMC
1
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
2
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
3
5 Things to Know About HHS's Interim Peptide Compounding Policy
4
Experts Pitch National Risk Pool to Fund Gene Therapy Access
5


